Publikationen, an denen er mitarbeitet Celia Miralles Álvarez (10)

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

2011

  1. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/Hepatitis C virus-coinfected patients treated for chronic hepatitis C

    Clinical Infectious Diseases, Vol. 53, Núm. 12, pp. 1291-1295

2010

  1. Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C

    AIDS Research and Human Retroviruses, Vol. 26, Núm. 4, pp. 419-424

2009

  1. (Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))

    Enfermedades Infecciosas y Microbiologia Clinica

2007

  1. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients

    Journal of Acquired Immune Deficiency Syndromes, Vol. 45, Núm. 4, pp. 439-444

  2. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients

    Journal of Viral Hepatitis, Vol. 14, Núm. 6, pp. 387-391

  3. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin

    Antiviral Therapy, Vol. 12, Núm. 4, pp. 469-476

  4. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 8, pp. 972-982

2005

  1. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C

    Antiviral Therapy, Vol. 10, Núm. 5, pp. 657-662